The new solution expands the capabilities of the BD UltraSafe Plus™ needle guard platform to provide biologics up to 2 mL and 30 cP-enhanced self-administration
Franklin Lake, New Jersey, USA, November 17, 2021 / B3C News Line/ - The world's leading medical technology company BD (Becton, Dickinson and Company) (NYSE: BDX) today announced the launch of BD UltraSafe Plus™ 2.25 The passive needle guard used by mL Pharmaceuticals in drug-device combination products. When combined with a glass pre-filled syringe, the BD UltraSafe Plus™ 2.25 mL system is capable of subcutaneously delivering biological solutions with different fill volumes up to 2 mL and viscosities up to 30 cP.
BD UltraSafe Plus™ 2.25 mL is the latest solution commercially released to the BD combination product drug delivery system portfolio, designed to meet the needs of healthcare providers, patients, and caregivers for manual injection of biological solutions. The unique design of BD UltraSafe Plus™ 2.25 mL complements the biopharmaceutical company’s combined product strategy to achieve patient controlled injection of complex, high-viscosity drugs.
Biological therapies are usually self-administered by patients or caregivers, and a drug delivery system that provides ease of use and safety advantages in a non-clinical environment is required. However, the viscosity and injection volume of biologics have been increasing in the past few years (>1 mL, >10 cP), which exceeds the capabilities of many commercial injectable drug delivery systems. Biological preparations with high volume and viscosity usually require stronger injection force, which may present challenges from the user's point of view.
"With BD UltraSafe Plus™ 2.25 mL, we are innovating the drug delivery system. The goal is to provide patients with confidence and ease of use, improve their self-injection experience, and serve the ever-expanding biological drug delivery design space," said Eric Borin , BD Medical-Pharmaceutical Systems (1) Global President. "We are very pleased to be able to support the release of biopharmaceutical drugs with a new powerful platform technology compatible with BD Neopak™ 2.25 mL glass prefilled syringes, and to support our customers' high-speed assembly by leveraging the rich experience of BD UltraSafe™ passive needle guards Commercialized combination products."
When developing a patient-centric solution, BD UltraSafe Plus™ 2.25 mL was evaluated in a human factor verification study that proved usability, and most participants expressed confidence that the activated safety mechanism could protect them from Suffered from a needle stick injury (1).
BD is developing a series of innovative options for biopharmaceutical companies seeking to provide biologics in a dose volume of 2 mL, including BD Neopak™ glass pre-filled syringes, BD Neopak™ XtraFlow™ glass pre-filled syringes (2), BD Intevia™ disposable automatic Syringe (2) and BD UltraSafe Plus™ passive needle guard.
BD UltraSafe Plus™ 2.25 mL Passive Needle Guard is now available for development by biopharmaceutical companies.
For more information about the BD UltraSafe Plus™ passive needle guard, please visit: https://drugdeliverysystems.bd.com/products/safety-and-shielding-systems/ultrasafe-plus-passive-needle-guard
For high resolution, click on the image.
About BD BD is one of the world's largest medical technology companies, promoting the healthy development of the world by improving medical discovery, diagnosis and nursing services. The company supports heroes working on the front lines by developing innovative technologies, services and solutions to advance the clinical treatment of patients and the clinical process of healthcare providers. BD and its 65,000 employees are passionate about helping improve the safety and efficiency of the clinician's care delivery process, enabling laboratory scientists to accurately detect diseases and improving the ability of researchers to develop next-generation diagnostics and treatments. BD has operations in almost every country and cooperates with organizations around the world to solve some of the most challenging global health problems. By working closely with customers, BD can help improve results, reduce costs, increase efficiency, increase safety, and expand access to healthcare. In 2017, BD welcomed CR Bard and its products into the BD family.
Contact Trey Hollern Director of Public Relations +1 862.284.8629 This email address has been protected by an anti-spam plugin. You need to enable JavaScript to view it.
Nadia Goncalves Senior Director of Investor Relations This email address has been protected by anti-spam plugins. You need to enable JavaScript to view it. +1 201.847.5934
1. Human factor verification study-BD UltraSafe Plus™ 2.25 mL passive needle protection device (internal study), Le Pont-de-Claix, France; Becton, Dickinson and Company, 2019. 2. BD Intevia™ 2.25 mL disposable auto-injector and The BD Neopak™ XtraFlow™ 2.25 mL pre-filled syringe is a product under development; some statements are forward-looking and subject to various risks and uncertainties.
Keywords: humans; injections; syringes; self-management; health workers; caregivers; drug delivery systems; subcutaneous tissues; viscosity; biological products; biological therapy; technology; pharmaceutical preparations; North America
Published by the B3C news line
© B3C Group Co., Ltd.